The CellSearch® system, currently the only Food and Drug Administration (FDA)-approved platform for circulating tumor cells isolation, employs EpCAM-based immunomagnetic enrichment technology (38, 39), and CTCs provide a new way of thinking about diagnosing, treating, and following up on ovarian cancer. Here, EPCAM is linked to ovarian carcinoma.